SCHEMBL11997507

CCCC(=O)NC1C(O[C@@H]2CO[C@@H](O[C@@H]3C(CO)O[C@@H](OC4CO[C@@H](O[C@@H]5C(CO)O[C@@H](OCC(CCC)CCC)C(NC(=O)CCC)[C@H]5O)C[C@@H]4O)C(NC(=O)CCC)[C@H]3O)C[C@@H]2O)OC(COS(=O)(=O)O)[C@@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3OC(COS(=O)(=O)O)[C@@H](O[C@H]4C[C@H](O)[C@H](O)CO4)[C@H](O)C3NC(=O)CCC)CO2)[C@@H]1O

nearest known ligand 0.32

Predicted protein targets (top 7)

	gene	UniProt	supporting neighbours	confidence
▸	SELL	P14151	3/20	0.32

▸	TLR4	O00206	2/20	0.31

▸	BMP2	P12643	1/20	0.31

▸	VEGFA	P15692	1/20	0.31

▸	CXCL12	P48061	1/20	0.31

▸	SHH	Q15465	1/20	0.31

▸	SELP	P16109	2/20	0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL11997510	0.87	CA1 (0.33)	TLR4BMP2VEGFACXCL12SHH
SCHEMBL11997494	0.87	VEGFA (0.43)	TLR4BMP2VEGFACXCL12SHH
SCHEMBL11997495	0.84	VEGFA (0.43)	TLR4BMP2VEGFACXCL12SHH
SCHEMBL11997509	0.83	BMP2 (0.33)	BMP2VEGFACXCL12SHHSELP
SCHEMBL11997506	0.83	LGALS3 (0.35)	BMP2VEGFACXCL12SHHSELP
SCHEMBL11997503	0.81	CD69 (0.40)	BMP2VEGFACXCL12SHH
SCHEMBL11997501	0.81	CD69 (0.40)	BMP2VEGFACXCL12SHH
SCHEMBL11997502	0.81	CD69 (0.40)	BMP2VEGFACXCL12SHH
SCHEMBL11997500	0.81	CD69 (0.40)	BMP2VEGFACXCL12SHH
SCHEMBL11997493	0.79	VEGFA (0.50)	BMP2VEGFACXCL12SHHSELP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-9012413-B2	FGF receptor-activating N-acyl octasaccharides, preparation thereof, and therapeutic use thereof	SANOFI (FR)	2015-04-21	—	—	US	disclosed
US-20120214754-A1	FGF RECEPTOR-ACTIVATING N-ACYL OCTASACCHARIDES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF	SANOFI (FR)	2012-08-23	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20120214754-A1	FGF RECEPTOR-ACTIVATING N-ACYL OCTASACCHARIDES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF	FGFR1, FGF2, FGFR3	SELL 680/4885TLR4 334/4885BMP2 245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.